SCN SIGNS LOI WITH US PARTNER REGARDING COLDIZIN LAUNCH

Scandinavian Clinical Nutrition AB (SCN) has signed a Letter of Intent with the company’s US partner Inverness Medical Innovations, Inc. regarding mass market launch of the cold product Coldizin in USA.

As a part of ongoing negotiations regarding launch of SCN’s patented and trademark protected cold product Coldizin in USA, SCN has signed a Letter of Intent (LOI) with the company’s mass market partner Inverness Medical Innovations, Inc. The objective of the negotiations is to agree on terms for launching Coldizin in the fall of 2008 on the US mass market.

For more information, please contact:

Ulf Söderberg, CEO, us@scnutrition.com, +46 708 13 22 81

Thomas Christensen, CFO, tc@scnutrition.com, +47 922 55 444

Scandinavian Clinical Nutrition AB (publ) works in R&D and sales of scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina and Ledactin. Core competence and strategic alliances within both R&D and sales, in combination with innovative and scientifically documented products, create the right conditions for profitable growth on the international market. The shares of SCN are traded under the ticker “SCN” on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se).